首页> 美国卫生研究院文献>BMC Nephrology >Immune thrombocytopenic purpura presenting in a patient after renal transplant for diabetic nephropathy
【2h】

Immune thrombocytopenic purpura presenting in a patient after renal transplant for diabetic nephropathy

机译:肾移植术后糖尿病性肾病患者出现免疫性血小板减少性紫癜

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundImmune thrombocytopenic purpura (ITP) is primarily characterized by immune-mediated destruction of platelets in circulation. Major treatment options range from careful observation, steroids, immunosuppressive medications, immunoglobulins to splenectomy. Interestingly and rarely, ITP has also been reported after solid organ transplantation in patients receiving immunosuppressive medications. While the incidence of new onset ITP after solid organ transplant is comparatively well documented, new onset ITP after renal transplant has only been reported in two patients. Both these patients underwent renal transplant for underlying Immunoglobulin-A (IgA) nephropathy and were treated effectively with steroids. We present successful management of the first reported case of new-onset ITP presenting after renal transplant in a patient with underlying diabetic nephropathy. The case report discusses the potential management strategies in such a novel scenario aiming simultaneously for a well-functioning renal graft, adequate hemostasis, minimum therapy- related morbidity and least cost implications for the patient.
机译:背景技术免疫性血小板减少性紫癜(ITP)的主要特征是免疫介导的血小板循环破坏。主要治疗选择包括仔细观察,类固醇,免疫抑制药物,免疫球蛋白到脾切除术。有趣的是,很少有人报道了接受免疫抑制药物的实体器官移植后的ITP。固相器官移植后新发ITP的发生率已有相对较好的文献报道,但肾移植后新发ITP的发病率仅报道于两名患者。这些患者均因潜在的免疫球蛋白-A(IgA)肾病接受了肾脏移植,并接受了类固醇的有效治疗。我们目前成功治疗潜在的糖尿病肾病患者肾移植后新发ITP的第一例报道病例。病例报告讨论了在这种新型情况下的潜在治疗策略,旨在同时实现功能良好的肾移植,适当的止血,与治疗相关的最低发病率和对患者的成本影响最小。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号